Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors.

Abstract

BACKGROUND:

Oligodendroglial tumors are rare and chemosensitive diseases; but the overall results with current chemotherapy regimens cannot be considered satisfactory and other active treatments are necessary. We decided to determine the efficacy and toxicity profile of the carboplatin and etoposide (CE) regimen in this setting.

METHODS:

In this phase II trial we evaluated the response rate of first or second line CE regimen (Carboplatin AUC 5 on day 1 and Etoposide 120 mg/m2 on days 1-3 every 28 days) in patients with recurrent/progressive oligodendroglial tumors.

RESULTS:

Thirty-two patients were enrolled. Median age was 42 years (range 22-66); median ECOG PS was 0 (range 0-2); 9 patients had oligodendroglioma, 3 patients had oligoastrocytoma, 11 patients had anaplastic oligodendroglioma, 9 patients had anaplastic oligoastrocytoma. CE regimen showed a response rate of 46.9% with 5 complete responses (15.6%) and 10 partial responses (31.3%). Eleven patients (34.4%) had stable disease. Median time to progression was 8 months, progression-free survivals at 6 and 12 months were 80% and 46.9%, respectively. Toxicity was mainly hematological, with grade 3-4 neutropenia in 5 (15.6%) patients.

CONCLUSIONS:

In this trial CE regimen has shown relevant activity with a favourable safety profile.

• Authors: Luciano Scopece, Enrico Franceschi, Giovanna Cavallo, Anna Paioli, Gabriele Paioli, Rosa Conforti, Emanuela Palmerini, Carlotta Berzioli, Federica Spagnolli, Roberta Degli Esposti, Lucio Crinò
• Journal: Journal of neuro-oncology (J Neurooncol) Vol. 79 Issue 3 Pg. 299-305 (Sep 2006) ISSN: 0167-594X [Print] United States
• PMID: 16645720 (Publication Type: Clinical Trial, Phase II, Journal Article)

Chemical References

• Etoposide
• Carboplatin

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Brain Neoplasms (drug therapy, mortality, pathology)
• Carboplatin (administration & dosage, adverse effects)
• Disease-Free Survival
• Etoposide (administration & dosage, adverse effects)
• Female
• Glioma (drug therapy, mortality, pathology)
• Humans
• Loss of Heterozygosity
• Male
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy)
• Survival Analysis
• Treatment Outcome